Abstracts tagged "Anti-TNF therapy and spondylarthropathy"

Abstract Number: 2229 • 2012 ACR/ARHP Annual Meeting
Analysis of Clinical, CRP- and MRI- Responses to TNF-Blockade in Axial Spondyloarthritis Patients with Short Vs Long Symptom Duration
Anja Weiss¹, In-Ho Song², Hildrun Haibel², Joachim Listing³ and Joachim Sieper⁴, ¹German Rheumatism Research Centre, Berlin, Germany, ²Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: To investigate the impact of disease duration on treatment response in patients with axial spondylarthritis (SPA) treated with etanercept (ETA) or adalimumab (ADA). Methods:…
Abstract Number: 2220 • 2012 ACR/ARHP Annual Meeting
Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry
Andreas M. Reimold¹, Liron Caplan², Daniel O. Clegg³, Gail S. Kerr⁴, Elizabeth Chang⁵, Lisa A. Davis⁶, Prashant Kaushik⁷, Vikas Majithia⁸, J. Steuart Richards⁹, Joel D. Taurog¹⁰ and Jessica Walsh¹¹, ¹Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ²Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ³Division of Rheumatology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Phoenix VAHCS, Phoenix, AZ, ⁶Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁷Department of Medicine, Sratton VAMC, Albany, NY, ⁸Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ⁹Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ¹⁰Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Rheumatology, University of Utah Hospital, Salt Lake City, UT
Background/Purpose: The spondyloarthritides are a group of conditions characterized by inflammation in the axial skeleton or peripheral joints. The arthritis may present as the primary…
Abstract Number: 539 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab for the Treatment of Peripheral Arthritis in Spondyloarthritis Patients without Ankylosing Spondylitis or Psoriatic Arthritis
Jacqueline E. Paramarta¹, Leen De Rycke², Tanja F. Heijda², Carmen A. Ambarus³, Koen Vos², Huib J. Dinant², Paul P. Tak² and Dominique L. Baeten², ¹Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The treatment of spondyloarthritis (SpA) has improved dramatically since the introduction of TNF-blockade. However, this therapy is only approved and reimbursed for the treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].